IRIS
RUBAGOTTI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 15.821
Totale 15.821
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 15.821
Totale 15.821
Salva come PNG Salva come JPEG
Città #
Genova 12.116
Rapallo 1.651
Genoa 1.212
Vado Ligure 812
Bordighera 30
Totale 15.821
Salva come PNG Salva come JPEG
Nome #
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 174
Adjuvant immunochemotherapy in colorectal cancer Dukes C. 167
Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials 154
A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group. 150
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 150
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 143
A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. 135
Differential expression of nuclear lamins in normal and cancerous prostate tissues 135
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. 133
Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast 133
Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. 133
"Autologous Bone Marrow Transplantation for Adult Advanced Stage Lymphoblastic Lymphoma in First CR. A Study of the NHLCSG". 130
Switching to aromatase inhibitors in early breast cancer. 129
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 125
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 124
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial. 123
Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery 123
Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? 121
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials 121
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. 121
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 121
Enterolactone in breast cyst fluid: correlation with EGF and breast cancer risk. 119
Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. 119
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. 118
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 117
Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial. 116
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. 116
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. 115
Carboplatin, Doxorubicin, and Cyclophosphamide Versus Cisplatin, Doxorubicin, and Cyclophosphamide: a Randomized Trial in Stage III-IV Epithelial Ovarian Carcinoma" 114
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 113
Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study. 113
Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer. 112
Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study. 112
Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer 111
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. 111
Periostin: A Novel Prognostic and Therapeutic Target For Genitourinary Cancer? 111
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 111
The impact of received dose intensity on the outcome of advanced ovarian cancer. 110
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. 110
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study 110
Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results 110
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen. Results of the GROCTA trial. 109
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer. 108
84: [Antibiotic preparation in operations on the large intestine. Experimental study] GF, Rollandi GA. 107
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 107
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial 106
Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death 106
48: Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. 105
Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. 105
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 105
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 105
Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients. 104
Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study. 104
Randomized cooperative study of perioperative chemotherapy in breast cancer. 104
Prognostic value of nuclear matrix protein expression in localized prostate cancer. 104
A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients. 103
Randomized trial of chemoimmunotherapy in advanced non-oat-cell lung cancer. 103
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. 103
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study 102
Fattibilità della Terapia Adiuvante Intraperitoneale e Sistemica in Pazienti Operati Radicalmente per Carcinoma del Colon. 101
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. 101
High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. 101
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. 100
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer 100
Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients 100
Etoposide v etoposide and cisplatin in the treatment of advanced non-small cell lung cancer: a FONICAP randomized study. 99
Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. 99
The prognostic value of stromal and epithelial periostin expression in human breast cancer: Correlation with clinical pathological features and mortality outcome 99
68P * Prognostic value of periostin (PN) expression in early breast cancer (BCa): Long-term mortality outcomes 99
Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). 98
Cerebral metastases secondary to ovarian cancer: still an unusual event. 97
Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast. 97
Gynaecomastia: the anastrozole paradox 97
Stimulation of human breast cancer in vivo. Experimental findings and clinical results. 97
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. 96
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 96
Chemotherapy (CT) versus tamoxifen (T) versus chemoterapy plus tamoxifen (CTT) in patients with node-positive (N+), estrogen receptor-positive (ER+) breast cancer (bca): Very late results of an Italian multicentric trial 96
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer. 96
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials 95
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. 94
Epidemiology of kidney cancer 94
Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study. 93
Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial. 93
Impact of irradiation of residual breast on adjuvant chemotherapy dose intensity. 92
Safety of antiandrogen therapy for treating prostate cancer. 92
Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group 91
VACOP-B Versus VACOP-B Plus Autologous Bone Marrow Transplantation for Advanced Diffuse Non-Hodgkin's Lymphoma: Results of a Prospective Randomized Trial by the Non-Hodgkin's Lymphoma Cooperative Study Group 91
Chemoradiotherapy in locally advanced bladder cancer: neoadjuvant and definitive treatment 91
Enterolactone as a risk factor for breast cancer: A review of the published evidence 91
A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. North-West Oncology Group (GONO) Study, Italy. 90
A. Lettera a: Journal of Clinical Oncology, 1987; 5, N. 4. 89
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials 89
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, esrogen receptor-positive breast cancer patients: results of a multicentric Italian study. 88
High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow. 1999 Apr;33(3-4):321-30 88
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 87
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial 86
Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study 86
Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly. 85
Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study 85
O-4 Ovarian suppression (OS) and tamoxifen (TAM) as an alternative to chemotherapy in early breast cancer. Long-term results of the GROCTA02 trial 84
Totale 10.846
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.399
article - articoli 45.336
book - libri 0
conference - conferenze 161
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.902
Totale 96.798
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.671 0 0 0 0 432 469 659 271 364 806 511 159
2020/20211.053 60 110 83 104 43 105 49 92 112 127 78 90
2021/20222.055 47 135 131 261 75 154 74 550 113 190 53 272
2022/20231.959 195 106 24 203 368 400 1 143 347 9 135 28
2023/2024906 49 143 16 100 90 156 54 65 35 30 53 115
2024/2025842 54 237 89 195 267 0 0 0 0 0 0 0
Totale 16.089